↓ Skip to main content
What is this page? Embed badge

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
32 X users

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
104 Mendeley
Summary X Dimensions citations
So far, Dimensions has found 88 publications that cite this research output.

88

The most recent citing publications are shown below. View all 88 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.